Mer­ck­'s Keytru­da un­corks full da­ta on lat­est ad­ju­vant win — this time in melanoma — adding bricks to ear­ly can­cer wall

In re­cent months, the bat­tle for PD-(L)1 dom­i­nance has spilled over in­to ear­ly can­cer with Mer­ck’s Keytru­da and Bris­tol My­ers Squibb’s Op­di­vo all alone on the front lines. Keytru­da now has an­oth­er shell in its ban­dolier, and it could spell a quick ap­proval.

Keytru­da cut the risk of re­lapse or death by 35% over place­bo (p=0.00658) in high-risk, stage 2 melanoma pa­tients who had pre­vi­ous­ly un­der­gone surgery to re­move their tu­mors, ac­cord­ing to full da­ta from the Phase III KEYNOTE-716 pre­sent­ed Sat­ur­day at #ES­MO21.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER